All development and commercialization rights for MP0310, a clinical stage immunomodulator intended to treat solid tumors, will be reverted to Molecular Partners.
A new approach to improving a patient’s ability to recover from a stroke is discussed in an article published this month in Science Translational Medicine.
The WHO has indicated support for Pfizer’s Paxlovid and reversing a previous decision on using antiviral remdesivir, now recommending it in cases of mild to moderate COVID-19.
New research investigates the role chaperone-mediated autophagy (CMA) can play in preventing atherosclerosis, a thickening or hardening of the arteries.
Researchers at Albert Einstein College of Medicine have cleverly developed a vaccine for pancreatic cancer by using the adaptive immunity already present in nearly all of the global population.
Pfizer issued a statement on Monday regarding a voluntary recall of three of its products. The recall affects eleven lots of hypertension medications in total.
Merck’s Keytruda has become an approved treatment for yet another indication: unresectable or metastatic advanced endometrial carcinoma. Know more about it here.
Lamassu Bio, Inc. is setting its sights on the unmet needs of the pharmaceutical industry as it announces a new venture to develop therapeutics for cancer.
Araclon Biotech of Spain revealed positive data from the first part of a phase II trial for its immunotherapeutic vaccine to prevent Alzheimer’s disease- ABvac40.
An investigation into the estrogen-brain link will be led by the Tulane Brain Institute’s multidisciplinary team, whose expertise spans across the pharmacology, physiology and molecular biology industries.
